Abcellera Biologics Stock Performance
| ABCL Stock | USD 2.95 0.19 6.88% |
On a scale of 0 to 100, Abcellera Biologics holds a performance score of 6. The firm shows a Beta (market volatility) of 1.14, which signifies a somewhat significant risk relative to the market. Abcellera Biologics returns are very sensitive to returns on the market. As the market goes up or down, Abcellera Biologics is expected to follow. Please check Abcellera Biologics' sortino ratio, semi variance, and the relationship between the standard deviation and value at risk , to make a quick decision on whether Abcellera Biologics' price patterns will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Abcellera Biologics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite quite weak fundamental indicators, Abcellera Biologics disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 8.15 | Five Day Return 10.97 | Year To Date Return (47.91) | Ten Year Return (94.93) | All Time Return (94.93) |
1 | Acquisition by Thermopylae Holdings Ltd. of 9173 shares of Abcellera Biologics at 8.0499 subject to Rule 16b-3 | 08/30/2024 |
2 | AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 | 09/26/2024 |
3 | Acquisition by Carl Hansen of 56125 shares of Abcellera Biologics at 2.7 subject to Rule 16b-3 | 09/27/2024 |
4 | AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer Annual Meeting 2024 | 10/04/2024 |
5 | AbCellera A Platform To Pipeline Transition - Seeking Alpha | 10/14/2024 |
6 | AbCellera Reports Q3 2024 Business Results | 11/04/2024 |
7 | AbCellera Biologics Q3 2024 Earnings Call Transcript | 11/05/2024 |
8 | AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 | 11/07/2024 |
9 | Acquisition by Booth Andrew of 14000 shares of Abcellera Biologics at 14.61 subject to Rule 16b-3 | 11/08/2024 |
10 | ABCL Owner Earnings per Share -0.61 - GuruFocus.com | 11/22/2024 |
| Begin Period Cash Flow | 414.6 M |
Abcellera |
Abcellera Biologics Relative Risk vs. Return Landscape
If you would invest 256.00 in Abcellera Biologics on August 28, 2024 and sell it today you would earn a total of 39.00 from holding Abcellera Biologics or generate 15.23% return on investment over 90 days. Abcellera Biologics is currently generating 0.2958% in daily expected returns and assumes 3.847% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Abcellera, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Abcellera Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Abcellera Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Abcellera Biologics, and traders can use it to determine the average amount a Abcellera Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0769
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ABCL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.85 actual daily | 34 66% of assets are more volatile |
Expected Return
| 0.3 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Abcellera Biologics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Abcellera Biologics by adding it to a well-diversified portfolio.
Abcellera Biologics Fundamentals Growth
Abcellera Stock prices reflect investors' perceptions of the future prospects and financial health of Abcellera Biologics, and Abcellera Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Abcellera Stock performance.
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (14.39) % | ||||
| Current Valuation | 243.47 M | ||||
| Shares Outstanding | 295.37 M | ||||
| Price To Earning | 16.67 X | ||||
| Price To Book | 0.76 X | ||||
| Price To Sales | 24.73 X | ||||
| Revenue | 38.02 M | ||||
| Gross Profit | 311.11 M | ||||
| EBITDA | (192.16 M) | ||||
| Net Income | (146.4 M) | ||||
| Cash And Equivalents | 868.21 M | ||||
| Cash Per Share | 3.04 X | ||||
| Total Debt | 77.38 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 9.86 X | ||||
| Book Value Per Share | 3.65 X | ||||
| Cash Flow From Operations | (43.88 M) | ||||
| Earnings Per Share | (0.61) X | ||||
| Market Capitalization | 815.21 M | ||||
| Total Asset | 1.49 B | ||||
| Retained Earnings | 279.79 M | ||||
| Working Capital | 752.97 M | ||||
About Abcellera Biologics Performance
By examining Abcellera Biologics' fundamental ratios, stakeholders can obtain critical insights into Abcellera Biologics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Abcellera Biologics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 7.58 | 7.46 | |
| Return On Tangible Assets | (0.11) | (0.11) | |
| Return On Capital Employed | (0.17) | (0.16) | |
| Return On Assets | (0.10) | (0.09) | |
| Return On Equity | (0.13) | (0.12) |
Things to note about Abcellera Biologics performance evaluation
Checking the ongoing alerts about Abcellera Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Abcellera Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Abcellera Biologics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 38.02 M. Net Loss for the year was (146.4 M) with profit before overhead, payroll, taxes, and interest of 311.11 M. | |
| Abcellera Biologics currently holds about 868.21 M in cash with (43.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Abcellera Biologics has a frail financial position based on the latest SEC disclosures | |
| Roughly 28.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: ABCL Owner Earnings per Share -0.61 - GuruFocus.com |
- Analyzing Abcellera Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Abcellera Biologics' stock is overvalued or undervalued compared to its peers.
- Examining Abcellera Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Abcellera Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Abcellera Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Abcellera Biologics' stock. These opinions can provide insight into Abcellera Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.61) | Revenue Per Share 0.112 | Quarterly Revenue Growth (0.01) | Return On Assets (0.13) |
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.